DE69022678T2 - S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. - Google Patents

S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.

Info

Publication number
DE69022678T2
DE69022678T2 DE69022678T DE69022678T DE69022678T2 DE 69022678 T2 DE69022678 T2 DE 69022678T2 DE 69022678 T DE69022678 T DE 69022678T DE 69022678 T DE69022678 T DE 69022678T DE 69022678 T2 DE69022678 T2 DE 69022678T2
Authority
DE
Germany
Prior art keywords
ibuprofen
amino acid
lysine
analgesics
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69022678T
Other languages
English (en)
Other versions
DE69022678D1 (de
Inventor
King Chiu Kwan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69022678D1 publication Critical patent/DE69022678D1/de
Publication of DE69022678T2 publication Critical patent/DE69022678T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/08—Saturated compounds having a carboxyl group bound to a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

1. Kristallines S(+)-Ibuprofen-L-lysin, das im wesentlichen frei von irgendeinem anderen Ibuprofen-lysin-Stereoisomer ist.
2. Die Verbindung nach Anspruch 1, worin das Gewichtsverhältnis von S(+)-Ibuprofen-L-lysin zu anderen Stereoisomeren wenigstens 95:5 ist.
3. Die Verbindung nach Anspruch 1, worin das Gewichtsverhältnis wenigstens 99:1 ist.
4. Eine pharmazeutische Zusammensetzung, die eine wie in irgendeinem der Ansprüche 1 bis 3 beanspruchte Verbindung und einen nicht toxischen, pharmazeutisch annehmbaren Träger umfaßt.
5. Die Verwendung einer wie in irgendeinem der Ansprüche 1 bis 3 beanspruchten Verbindung für die Herstellung eines Medikaments zur Schmerzund Endzündungsbehandlung bei einem Menschen.
DE69022678T 1989-10-17 1990-10-11 S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential. Expired - Fee Related DE69022678T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42246689A 1989-10-17 1989-10-17

Publications (2)

Publication Number Publication Date
DE69022678D1 DE69022678D1 (de) 1995-11-02
DE69022678T2 true DE69022678T2 (de) 1996-03-21

Family

ID=23675012

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69022678T Expired - Fee Related DE69022678T2 (de) 1989-10-17 1990-10-11 S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.

Country Status (10)

Country Link
EP (1) EP0424028B1 (de)
JP (1) JPH03206064A (de)
KR (1) KR910007858A (de)
AT (1) ATE128452T1 (de)
AU (1) AU635074B2 (de)
CA (1) CA2027624A1 (de)
DE (1) DE69022678T2 (de)
DK (1) DK0424028T3 (de)
IE (1) IE68508B1 (de)
PT (1) PT95564B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
HUT59653A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing complexes containing s/+/-phenyl-alcanoic acids and alpha-hydroxy-alcanoic acids and pharmaceutical compositions containing them as active components
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
FR2687673B1 (fr) * 1992-01-13 1995-07-07 Jung Jean Sels amines d'acides arylcarboxyliques, sterilisables, solubles dans l'eau, utilises en ophtalmologie et/ou dans la sphere otorhinolaryngologique.
ATE151740T1 (de) * 1992-12-02 1997-05-15 Knoll Ag Verfahren zur herstellung von im wesentlichen enantiomeren der phenylpropionsäuren
IT1264856B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica ad attivita' analgesica
IT1264855B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
IT1266583B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Processo per la preparazione di sali dell'acido 2-(4-isobutilfenil)- propionico
EP0740935A4 (de) * 1994-02-24 1999-06-16 Otsuka Pharma Co Ltd Verstärker der analgetischen aktivität
ES2105948B1 (es) * 1994-10-31 1998-07-01 Zambon Spa Procedimiento para la preparacion de sales de acido 2-(4-isobutilfenil) propionico.
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
AU737199B2 (en) * 1997-09-17 2001-08-09 Strategic Science & Technologies, Llc A delivery of arginine to cause beneficial effects
KR100523242B1 (ko) * 2000-05-18 2005-10-24 한미약품 주식회사 이부프로펜을 함유하는 정제 조성물
ES2429443T3 (es) 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ES2303468B1 (es) * 2007-01-22 2009-06-08 Masterfarm, S.L "una composicion farmaceutica pulverulenta que comprende ibuprofeno".
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
CN101978955A (zh) * 2010-11-05 2011-02-23 航天中心医院 右旋布洛芬氨基酸盐片剂及其制备方法
JP2014504592A (ja) 2010-12-29 2014-02-24 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 勃起不全および他の適応症の処置
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH377368A (de) * 1960-04-07 1964-05-15 Inventa Ag Verfahren zur Reinigung von 1(+)-Lysin
IT1059677B (it) * 1974-03-22 1982-06-21 Neopharmed Spa Sale di lisina ad azione terapeutica
DE3669103D1 (de) * 1986-11-14 1990-04-05 Puetter Medice Chem Pharm Ibuprofen enthaltendes arzneimittel.
US4851444A (en) * 1987-07-10 1989-07-25 Analgesic Associates Onset-hastened/enhanced analgesia

Also Published As

Publication number Publication date
DK0424028T3 (da) 1996-01-29
JPH03206064A (ja) 1991-09-09
CA2027624A1 (en) 1991-04-18
PT95564B (pt) 1997-11-28
EP0424028B1 (de) 1995-09-27
IE68508B1 (en) 1996-06-26
AU6469290A (en) 1991-04-26
EP0424028A3 (en) 1992-06-10
IE903717A1 (en) 1991-04-24
DE69022678D1 (de) 1995-11-02
KR910007858A (ko) 1991-05-30
AU635074B2 (en) 1993-03-11
EP0424028A2 (de) 1991-04-24
ATE128452T1 (de) 1995-10-15
PT95564A (pt) 1991-08-14

Similar Documents

Publication Publication Date Title
DE69022678T2 (de) S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.
DE69409969T2 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
DE69329400T2 (de) L-Dopa Ester enthaltende Zusammensetzung
DE69414720T2 (de) Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
DE3907649C2 (de) Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung
DE3424781C2 (de) Verwendung von L-Carnosin zur Tumorbehandlung
DE69202166T2 (de) Verwendung von Tetrahydrothienopyridinderivate als Angiogenese-Inhibitoren.
DE2451161A1 (de) Stabile prostaglandin-e-gruppen enthaltende arzneimittelzubereitung sowie verfahren zu deren herstellung
DE2900887A1 (de) Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit
DE3907688C2 (de) Salze von ungesättigten Fettsäuren mit Aminosäuren, Verfahren zu ihrer Herstellung sowie die Verwendung der ersteren und von weiteren derartigen Salzen
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
EP1154766B1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
DE2353797A1 (de) Stabilisierung von prostaglandinen
DE69307895T2 (de) Therapeutische verwendung von phosphoryl-l-serin-n-acyl-sphingosin
DE3538619A1 (de) Arzneimittel, die isomere des hydroxyprolin enthalten
DE69023939T2 (de) Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.
CH647677A5 (de) 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung.
CH624098A5 (de)
EP0493662A1 (de) Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
EP0223850B1 (de) Arzneimittel, die derivate des prolin oder hydroxyprolin enthalten
DE2633891C2 (de) Tris-(hydroxymethyl)-aminomethansalz der 2-(5-Benzoylthienyl)-α-methylessigsäure, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen
DE2131679A1 (de) 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate
DE2318784A1 (de) N-(2,4-dihydroxybenzoyl)-4-aminosalizylsaeure
DE2605243A1 (de) Pyrazolessigsaeurehaltiges arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee